Anti-EPM2A (Laforin, Lafora PTPase, LAFPTPase)

EPM2A:Laforin is a novel dual-specificity phosphatase which associates with polyribosomes and belongs to the protein-tyrosine phosphatase family. Two isoforms of Laforin are reported which have alternate C termini and a common segment that consists of a carbohydrate-binding module and a dual-specificity protein phosphatase domain. Laforin plays an important role in the regulation of glycogen metabolism, prevents the formation of polyglucasans, and hydrolyze phosphotyrosine and phosphoserine:threonine substrates. Malin, a ubiquitin ligase, helps in regulation of Laforin protein concentration. Laforin not only interacts with itself but also with PPP1R5, HIRIP5 and EPM2AIP1. Mutations in the gene encoding EPM2A have been associated with myoclonic epilepsy type 2 (EPM2), also known as Lafora disease, an autosomal recessive and severe form of adolescent-onset progressive epilepsy. Multiple transcript variants of Laforin are expressed in most of the tissues, including brain. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 0.25-0.5ug/ml, Optimal dilutions to be determined by the researcher. Positive Control: Human, mouse and rat heart lysate, Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.